The Role of IDH Inhibitors in Hematologic Malignancies

Slides:

Advertisements

Similar presentations

Targeted Therapy in Acute Myeloid Leukemia

Advertisements

Traditional Pathology Meets Next-Generation in Acute Myeloid Leukemia

Robert Farley University of Rhode Island Department of Biomedical Engineering.

Hematologic Malignancies

Stem cell concepts renew cancer research by John E. Dick Blood Volume 112(13): December 15, 2008 ©2008 by American Society of Hematology.

Center for Hematologic Malignancies

What the Future Holds in Targeting Cancer Metabolism

Fostering a Collaborative Approach in the Management of BRCA-Mutated Ovarian Cancer.

State of the Art in BRCA-Mutated Ovarian Cancer

New Molecular Abnormalities Recognized in AML

CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: Implementing Paradigms in Clinical Practice.

Program Goals. Program Goals Immunotherapy of B-cell Malignancies.

Neoplastic blood cells become pluripotent

An Introduction to DNA Damage Repair in Cancer: Beyond PARP

Bone-Targeted Therapy in the Adjuvant Breast Cancer Setting

Cancer Metabolism: A New Treatment Approach

What to Do Next: Sequencing of Therapy in Patients With Metastatic CRC

CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: A Clinical Update

Discussion Outline Cells of the Immune System.

The Genomics of Cancer and Molecular Testing:

Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.

Program Goals. Targeting New Pathways for Overcoming Endocrine Resistance in Breast Cancer.

Cancer Stem Cell Therapies in Gastrointestinal Cancers

American Heart Association Scientific Sessions

PARP and Other DNA Damage Repair Inhibitors in Solid Tumors: An Update

Activity Goals. Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?

PARP Inhibitors and Cancer: What Do You Need to Know?

Bone-Targeted Therapy in the Adjuvant Breast Cancer Setting

Introduction. For Pulmonologists by Pulmonologists: Diagnosis of NSCLC in an Age of Biomarkers.

Management of Glioblastoma

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

Advances in Myeloid Malignancies

Counseling Patients About Germline BRCA Mutations

Management Challenges in CLL

Enzymatic reactions catalyzed by wild-type and mutant IDH enzymes.

Individualizing Care in Ovarian Cancer

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.

Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.

by R. Coleman Lindsley, and Benjamin L. Ebert

Mutational Testing to Select Novel Targeted Therapies in AML

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Advancing Care Across the Spectrum of Pancreatic Cancer

Preclinical Accelerators of Precision Medicine Todd R. Golub, M.D.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Myeloid Updates From the Summer Congresses

Locally Advanced Lung Cancer

CAD and HF Often Coexist

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.

New ELN Recommendations

The Changing Field of Melanoma: Ipilimumab.

Individualizing Therapy for Patients With CLL in the Community Practice Setting: Focus on Age and Comorbidities.

What's on the Horizon? Assessing New First-Line Paradigms for AML Patients Ineligible for Intensive Chemotherapy.

Nicholas E. Khan, Philip S. Rosenberg, Blanche P. Alter

How Can Precision Medicine in Oncology Refine Best Treatment Approach?

The Role of Measurable Residual Disease in AML

Quality Improvement and Molecular Profiling in Advanced Non-Small Cell Lung Cancer.

IDH Inhibitors in AML.

Targeting Apoptosis in AML

Moving Care Forward in Advanced Gastric Cancer

What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

Minimal Residual Disease and Hematologic Malignancies

Computed tomographic images from a patient with BRAFL597S-mutant metastatic melanoma responding to therapy with the MEK inhibitor TAK-733. Computed tomographic.

Current Status of Biomarkers for Immune Checkpoint Inhibitors

Delineation of the clinical course and evolution of BRAF mutation status in the seven patients with BRAF V600E mutation. Delineation of the clinical course.

Program. Applying the Data and Practical Recommendations for Tailoring Treatment Selections for AML.

Targeted compounds exhibit cancer-selective ex vivo drug responses in AML. A, waterfall plot that highlights the most potent cancer-selective drugs for.

Single-site disease progression after 9 months of response to therapy in the right hemipelvis visualized by diffusion-weighted whole-body MRI. Top, fusion.

Presentation transcript:

The Role of IDH Inhibitors in Hematologic Malignancies

AML What Is It and How Did It Get There?

Key Points From De Novo AML Genome Atlas-1

AML A Long List of Prognostic Features

Selected Targeted Therapy in AML

The Evolution of the Discovery of IDH Mutations in Cancer by Year

IDH Mutations Also Found in MDS, NHL and Range of Solid Tumors

IDH Mutations as a Target in AML

AG-221 Preclinical Data

Phase 1 Study of AG-120 in IDH1-Mutant Hematologic Malignancies

Phase 1 Study of AG-221 in IDH2-Mutant Hematologic Malignancies

Results of AG-221 Phase 1 Study

Responses With AG-221

Differentiation Effect in the Bone Marrow

IDH1 (AG-120) and IDH2 (AG-221) Inhibitors: Ongoing and Planned Studies

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)